Alteral Therapeutics Amends Nordicus Partners Stake

TL;DR

Alteral Therapeutics just updated its Nordicus Partners stake filing. Watch this space.

AI Summary

Alteral Therapeutics ApS filed an amendment to its Schedule 13D on November 5, 2024, regarding its holdings in Nordicus Partners Corp. The filing indicates a change in the beneficial ownership of Nordicus Partners Corp's common stock by Alteral Therapeutics ApS. Specific details on the percentage change or new ownership stake are not immediately available in this excerpt.

Why It Matters

This filing signals a potential shift in control or influence over Nordicus Partners Corp, which could impact its stock price and strategic direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate activist investor activity or significant stake-building, which may lead to volatility.

Key Players & Entities

• Alteral Therapeutics ApS (company) — Filing entity
• Nordicus Partners Corp (company) — Subject company
• 280 SOUTH BEVERLY DR. SUITE 505 (address) — Nordicus Partners Corp business address
• MESTERLODDEN 3A, 1. (address) — Alteral Therapeutics ApS business address

FAQ

Key Financial Figures

• $0.001 — ment relates is Common Stock, par value $0.001 per share (“Shares”). The C

Filing Documents

• formsc13da.htm (SC 13D/A) — 50KB
• 0001493152-24-043649.txt ( ) — 52KB

From the Filing

SC 13D/A 1 formsc13da.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nordicus Partners Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 28265K205 (CUSIP Number) Alteral Therapeutics ApS Dyrehavevej 3B DK-2930 Klampenborg Denmark (+45) 53 84 27 43 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 14, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 28265K205 13D/A Page 2 of 5 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Alteral Therapeutics ApS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) (b) 3. SEC USE ONLY 4. SOURCE OF FUNDS (see instructions) PF 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6. CITIZENSHIP OR PLACE OF ORGANIZATION Denmark NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7. SOLE VOTING POWER 12,652,279 8. SHARED VOTING POWER 9. SOLE DISPOSITIVE POWER 12,652,279 10. SHARED DISPOSITIVE POWER 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 12,652,279 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 25.75 14. TYPE OF REPORTING PERSON (see instructions) PN CUSIP No. 28265K205 13D/A Page 3 of 5 Pages Item 1. Security and Issuer. The issuer is Nordicus Partners Corporation, a Delaware corporation (the “Company”). The title of the class of equity securities to which this Statement relates is Common Stock, par value $0.001 per share (“Shares”). The Company’s principal executive office is: 280 South Beverly Dr., Suite 505, Beverly Hills, CA 90212. All share and per-share amounts in this Schedule reflect a 1-for-50 reverse stock split effectuated on March 8, 2022. Item 2. Identity and Background. (a) This Statement is being filed by Alteral Therapeutics ApS (the “Reporting Person”). The sole owner and officer of the Reporting Person is Allan Traugott Wehnert. (b) The Reporting Person’s and Mr. Wehnert’s business address is: Dyrehavevej 3B, DK-2930 Klampenborg, Denmark. (c) Mr. Wehnert is employed by Oricidin A/S, Dyrehavevej 3B, 2930 Klampenborg, Denmark. (d) Neither the Reporting Person nor Mr. Wehnert has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years, neither the Reporting Person nor Mr. Wehnert has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of any such proceeding was not or is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) The Reporting Person is a private limited company (Anpartsselskab) organized in Denmark. Mr. Wehnert is a citizen of Denmark. Item 3. Source or Amount of Funds or Other Consideration. See Item 4. Item 4. Purpose of Transaction. On May 13, 2024, the “Company and certain shareholders (the “Sellers”) of Orocidin A/S, a Danish stock corporation (“Orocidin”), entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock. In exchange, the Company issued 38,000,000 restricted sha

View Full Filing

View this SC 13D/A filing on SEC EDGAR